Drug Profile
Research programme: Alzheimer's disease immunotherapy - Alterity Therapeutics
Alternative Names: 4E10Latest Information Update: 17 Apr 2019
Price :
$50
*
At a glance
- Originator Prana Biotechnology
- Developer Alterity Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 08 Apr 2019 Prana Biotechnology is now called Alterity Therapeutics
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in Australia (Parenteral)
- 23 Feb 2011 Preclinical development is ongoing in Australia